Tumour Angiogenesis is the first comprehensive book to cover all areas of this rapidly expanding research area. Each chapter is written by world experts in the field and topics covered include in vivo models, mechanisms, inhibition, and the role of macrophages, cytokines, proteases, extracellular matrix components, nitric oxide, prostanoids and oncogenes/tumour suppressor genes in angiogenesis. Other chapters examine the role of specific growth factors in angiogenesis - these include vascular endothelial growth factor, the basic fibroblast growth factor family, transforming growth factor-beta, tumour necrosis factor-alpha, platelet-derived endothelial cell growth factor/thymidine phosphorylase and pleiotrophin and related molecules. Clinical issues are addressed in chapters that deal with the prognostic and predictive value of tumour microvessel density and the therapeutic significance of microregional blood flow. The two final chapters examine the feasibility of targeting tumour vasculature using either antibodies or gene therapy.
Dr Roy Bicknell, Imperial Cancer Research Fund, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxon OX3 9DU, Tel (1865) 222421, Fax (1865) 222431, email: bicknelr.@icrf.icnet.uk; Dr C E Lewis, Senior Lecturer, Department of Pathology, University of Sheffield Medical School, Royal Hallamshire Hospital, Sheffield S10 2JF, Tel (0114) 271 2903, Fax (0114) 278 0059 Dr N Ferrara, Department of Cardiovascular Research,
Grenentech Inc, South San Francisco, California, USA,